Common Stock, par value $0.001 per share
- Symbol
- CVKD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
Cadrenal Therapeutics, Inc.
Regulation FD Disclosure · Other Events
Item 8.01. Other Events. On October 7, 2026, the Company issued a press release announcing that its Board of Directors has authorized the Company to initiate a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.…
Company context
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company’s pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency for the treatment of platelet-activating factor 4 disorders. Second-generation 12-LOX oral therapeutics (CAD-2000) are also in development for chronic indications.
Current securities
Registered securities in this filing
Cadrenal Therapeutics, Inc. · 8-K · Filed 2026-10-07
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01.
Other Events.
On
October 7, 2026, the Company issued a press release announcing that its Board of Directors has authorized the Company to initiate a formal
strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. Potential opportunities may
include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations,
or other strategic transactions. The strategic review is at a preliminary stage, and the Company has not set a deadline or definitive
timetable for the completion of the process. There can be no assurance that the strategic process will result in any transaction or other
strategic outcome.
Filed exhibits (1)
Exhibit 99.1 CADRENAL THERAPEUTICS RETAINS TUNGSTEN ADVISORS TO LEAD FORMAL STRATEGIC PROCESS TO MAXIMIZE VALUE OF ITS ORPHAN THROMBO-INFLAMMATORY THERAPEUTICS Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005 Cadrenal has received strong interest from potential strategic partners Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions PONTE VEDRA, Fla., October 7, 2026 (GLOBE NEWSWIRE) - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. The initiative builds on Cadrenal’s ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the Company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the Company’s …
Open exhibit ↗